STOCK TITAN
  1. Home
  2. News
  3. GOVX

GeoVax Labs, Inc. New - GOVX STOCK NEWS

Welcome to our dedicated page for GeoVax Labs New news (Ticker: GOVX), a resource for investors and traders seeking the latest updates and insights on GeoVax Labs New stock.

GeoVax Labs, Inc. (Nasdaq: GOVX) is a clinical-stage biotechnology company specializing in the development of human vaccines and immunotherapies against infectious diseases and cancers. Utilizing their innovative Modified Vaccinia Ankara-Virus-Like Particle (MVA-VLP) platform, GeoVax has a strong focus on creating vaccines that stimulate both humoral and cellular immune responses to various targeted infections.

GeoVax's product pipeline includes an advanced Covid-19 vaccine, GEO-CM04S1, which is currently undergoing three phase 2 clinical trials. This next-generation vaccine is designed to induce robust antibody and T-cell responses against multiple SARS-CoV-2 variants, including Delta and Omicron. GEO-CM04S1 is especially targeted at high-risk immunocompromised populations who may not respond adequately to existing vaccines.

In oncology, GeoVax is pioneering novel therapies with Gedeptin®, an oncolytic gene-directed therapy for solid tumors. Gedeptin® is in phase 1/2 clinical trials for advanced head and neck cancers, aiming to provide new treatment avenues for patients with limited options.

GeoVax has shown significant progress in vaccine development against other infectious diseases such as Mpox, smallpox, HIV, Zika, hemorrhagic fever viruses, and malaria. Their recent partnership with the National Institute of Allergy and Infectious Diseases (NIAID) has expanded their vaccine development license to include Mpox and smallpox, leveraging their MVA technology for broader immunological protection.

The company also focuses on intellectual property, holding over 115 granted or pending patents across 24 patent families. This robust IP portfolio enhances their competitive edge in the biopharmaceutical sector.

GeoVax's commitment to innovative research and scalable manufacturing solutions positions them as a key player in the fight against some of the world’s most threatening diseases. For more detailed information, visit their official website at www.geovax.com.

News

GeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine Congress

Rhea-AI Summary
GeoVax Labs, Inc. (GOVX) presented Phase 2 clinical trial data for its next-generation COVID-19 vaccine, GEO-CM04S1, at the World Vaccine Congress, demonstrating potent antibody and cellular immunity in immunocompromised patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.73%
Tags
clinical trial covid-19
-
News

Progress on GeoVax’s Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023

Rhea-AI Summary
GeoVax Labs, Inc. (Nasdaq: GOVX) presents preclinical vaccine efficacy data for GEO-CM02, a multi-antigen investigational SARS-CoV-2 vaccine, at the Vaccines Summit 2023 conference. The data demonstrate single-dose protection against multiple SARS-CoV-2 variants, including the Omicron variant, with a focus on inducing both antibodies and T-cell responses. The company is also evaluating its dual antigen COVID-19 vaccine, GEO-CM04S1, in three Phase 2 clinical trials, targeting immunocompromised patients and healthy individuals who have previously received the Pfizer or Moderna mRNA vaccine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.73%
Tags
none
-
News

GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update

Rhea-AI Summary
GeoVax Labs, Inc. (Nasdaq: GOVX) announced significant progress in its Phase 2 Program of GEO-CM04S1, a next-generation COVID-19 vaccine. The company presented safe administration and tumor reduction data for Gedeptin® at the AACR-AHNS Head and Neck Cancer Conference. They also secured a multi-product license for ProBioGen's AGE1.CR.pIX® suspension cell line to enhance manufacturing capabilities. The company will host a conference call and webcast today at 4:30 p.m. ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.64%
Tags
earnings
News

GeoVax to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 8, 2023

Rhea-AI Summary
GeoVax Labs, Inc. (Nasdaq: GOVX) will report its third quarter 2023 financial results on November 8, 2023, after the close of U.S. markets. The company will host a live conference call and webcast at 4:30 p.m. ET to provide a corporate update and discuss financial results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.41%
Tags
conferences earnings
-
News

GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine

Rhea-AI Summary
GeoVax Labs has commenced the planned site expansion for the Phase 2 clinical trial of its next-generation SARS-CoV-2 vaccine, GEO-CM04S1, in immunocompromised patients. The trial will enroll patients at multiple medical centers across the United States. The Phase 2 trial aims to evaluate the safety and immunogenicity of GEO-CM04S1 compared to Pfizer/BioNTech or Moderna mRNA-based vaccines in patients with hematologic malignancies who have received stem cell transplants or CAR T cell therapy. GeoVax believes that GEO-CM04S1 has the potential to offer a more robust and durable degree of protection for immunocompromised patients and as a booster vaccine for healthy individuals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.4%
Tags
clinical trial covid-19
-
News

GeoVax to Participate in Upcoming November Investor and Industry Events

Rhea-AI Summary
GeoVax Labs, Inc. to participate in four investor and industry events in November
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.12%
Tags
conferences
News

GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities

Rhea-AI Summary
GeoVax Labs, Inc. provides an update on key strategic initiatives, including advancements in their COVID-19 vaccine clinical programs and cancer therapy program. They have also received new patents for their vaccines. Initial data readouts from clinical trials are expected soon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
none
-
News

GeoVax Receives Notice of Allowance for Marburg Vaccine Patent

Rhea-AI Summary
GeoVax Labs receives patent allowance for Marburg virus vaccine, demonstrating 80% survival in nonhuman primate studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.21%
Tags
none
-
News

GeoVax Receives Notice of Allowance for HIV Vaccine Patent

Rhea-AI Summary
GeoVax Labs receives Notice of Allowance for patent application on HIV vaccine boost compositions and methods of use.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.56%
Tags
none
News

GeoVax to Participate in Upcoming October Investor and Industry Events

Rhea-AI Summary
GeoVax Labs, Inc. will provide updates on Phase 2 clinical trials for their COVID-19 vaccine and cancer immunotherapy programs. The Chairman and CEO will participate in upcoming investor and industry events, including the Emerging Growth Virtual Conference, BioFuture 2023, and Dawson James Small Cap Growth Conference. A live webcast of the Dawson James presentation will be available on GeoVax's website. One-on-one meetings with management will also be available at the conferences.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences

FAQ

What is the current stock price of GeoVax Labs New (GOVX)?

The current stock price of GeoVax Labs New (GOVX) is $2.95 as of November 22, 2024.

What is the market cap of GeoVax Labs New (GOVX)?

The market cap of GeoVax Labs New (GOVX) is approximately 24.0M.

What is GeoVax Labs, Inc.?

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancers using their MVA-VLP platform.

What is the MVA-VLP platform?

The MVA-VLP platform supports in vivo production of non-infectious virus-like particles that stimulate the immune system to fight targeted infections.

What are the main products in GeoVax’s pipeline?

GeoVax's key products include the GEO-CM04S1 Covid-19 vaccine and Gedeptin®, an oncolytic gene-directed therapy for solid tumors. They also have vaccines for Mpox, smallpox, and other infectious diseases under development.

What is the current status of the GEO-CM04S1 vaccine?

GEO-CM04S1 is currently in three Phase 2 clinical trials, targeting high-risk immunocompromised populations and evaluating its efficacy as a booster vaccine.

What is Gedeptin®?

Gedeptin® is GeoVax’s novel oncolytic gene-directed therapy for treating solid tumors, currently in Phase 1/2 clinical trials for advanced head and neck cancers.

How does GeoVax’s partnership with NIAID benefit their technology?

The partnership allows GeoVax to use NIAID's materials and patents to develop vaccines for Mpox, smallpox, and other infections using their MVA technology.

What recent achievements has GeoVax announced?

Recent achievements include positive interim results from Phase 2 trials for GEO-CM04S1, expanded licensing for Mpox and smallpox vaccines, and significant advancements in manufacturing capabilities.

How extensive is GeoVax’s intellectual property portfolio?

GeoVax holds over 115 granted or pending patents across 24 patent families, reinforcing their technological and competitive advantages in biotechnology.

What is the significance of GeoVax’s Covid-19 vaccine?

How can I learn more about GeoVax Labs, Inc.?

For detailed information, visit GeoVax’s official website at www.geovax.com.

Stock GOVX logo
GeoVax Labs, Inc. New

Nasdaq:GOVX

GOVX Rankings

#5218 Ranked by Market Cap
N/A Ranked by Dividends

GOVX Stock Data

24.00M
9.39M
0.52%
10.83%
3.53%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SMYRNA